Pretreatment thrombocytosis predict poor prognosis in patients with endometrial carcinoma: a systematic review and meta-analysis

Dan Nie,Zhengyu Li,E Yang

doi:10.1186/s12885-018-5264-y

Abstract

BackgroundSeveral previous studies have confirmed that thrombocytosis was related to reduced survival in many solid tumors. However, the prognostic significance of thrombocytosis in endometrial carcinoma (EC) was still controversy. Therefore, we conducted this study to assess the prognostic value of thrombocytosis in EC.MethodsThe database including PubMed, MEDLINE, EMBASE, and Web of Science was searched to explore available literature. Above all, the hazard ratio (HR), odds ratios (OR) with 95% confidence intervals (CIs) was used to investigate the correlation between thrombocytosis and overall survival (OS) and disease-free survival (DFS). Moreover, the association between thrombocytosis and patient clinicopathological characteristics was explored. Publication bias and sensitivity analysis also were conducted in this study.ResultsOverall, 11 studies involving 3439 patients were contained in this study. The results revealed that pretreatment thrombocytosis was significantly related to a decreased OS (pooled HR = 2.99; 95% CI = 2.35–3.8; P < 0.001) and DFS (pooled HR = 2.86; 95% CI = 2.27–3.6; P < 0.001) in patients with EC. Moreover, thrombocytosis was correlated with adverse clinicopathological parameters.ConclusionsPretreatment thrombocytosis is an adverse prognostic marker in patients with EC.

Highlights

Several previous studies have confirmed that thrombocytosis was related to reduced survival in many solid tumors
Selection criteria The including criteria were as follows: (1) endometrial carcinoma (EC) was diagnosed by histopathological examination; (2) platelet count was measured preoperation; (3) hazard ratios(HRs) and their 95% confidence intervals (CIs) for platelet count can be obtained; (4) the cut-off value of thrombocytosis was provided
The results revealed that elevated platelet count correlated with poor overall survival (OS) in EC patients (Fig. 2a)

Summary

Introduction

Several previous studies have confirmed that thrombocytosis was related to reduced survival in many solid tumors. It is urgently necessary to Previous studies have revealed that clinicopathological parameters such as histologic type and grade, FIGO stage, myometrial invasion, lymph node (LN) metastasis, lymphovascular space invasion (LVSI), tumor size, and the patients’ age has prognostic effect in patients with EC [5, 6]. These factors usually obtained postoperation and demonstrated to be insufficient to predict recurrence and estimate survival [5, 7, 8]. It is necessary to recognize more effective prognostic predictors to identify high-risk patients preoperation

Methods

Results

Discussion

Conclusion